Skip to main content

ADVL1622 Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors

NCT02867592

Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors

Associated Conditions

Multiple Tumor Types

Principal Investigator

Sponsor

Children's Oncology Group

The overall goals of this study are to: Find out what effects, good and/or bad, XL184 has on your tumor or type of cancer; to learn more about the side effects of XL184; to learn more about how XL184 works against cancer cells and other immune cells.